With the global advancement of sustainable development agendas and the “dual carbon” strategic goals, the pharmaceutical industry is facing significant challenges in its green transformation. Green pharmaceutical manufacturing must not only ensure drug quality and safety but also minimize resource consumption and waste emissions during production, thereby promoting the simultaneous enhancement of economic, environmental, and social benefits. This study proposes an integrated framework centered on the concept of “Quality by Green Design”, aiming to deeply integrate environmental compliance with quality management systems. By establishing this framework, environmental requirements are shifted from end-of-pipe treatment to design parameters at the R&D stage, fostering the simultaneous development of both “green” and “high-quality” attributes. This paper analyzes representative case studies from Taiji Group and Pfizer, demonstrating integrated approaches to green pharmaceutical manufacturing and their synergistic benefits. Integrating quality management with environmental compliance can improve production efficiency, reduce costs, mitigate risks, and enhance a company’s social responsibility image. The pharmaceutical industry should intensify efforts in green technology and digital transformation, promoting a shift from supply chain compliance to an ecosystem of value chain symbiosis, thereby advancing the vision of global green pharmaceutical manufacturing.
Liu et al. (Thu,) studied this question.